Skip to main content

Seizures clinical trials at UCLA

8 in progress, 3 open to eligible people

Showing trials for
  • Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

    open to eligible people ages 18-75

    The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.

    Los Angeles 5368361, California 5332921 and other locations

  • FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

    open to eligible people ages 18-75

    This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).

    Los Angeles 5368361, California 5332921 and other locations

  • Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

    open to eligible people ages 1 month to 18 years

    The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).

    Los Angeles 5368361, California 5332921 and other locations

  • LP352 in Children and Adults With Dravet Syndrome (DS)

    Sorry, not currently recruiting here

    This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.

    Los Angeles 5368361, California 5332921 and other locations

  • LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

    Sorry, accepting new patients by invitation only

    This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of 3 main phases: Screening, Titration period and Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 14 months.

    Los Angeles 5368361, California 5332921 and other locations

  • ZX008 in Subjects With CDKL5 Deficiency Disorder

    Sorry, in progress, not accepting new patients

    This is a multicenter, double-blind, parallel-group, placebo controlled, 2-part study to evaluate the efficacy and safety of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD).

    Los Angeles 5368361, California 5332921 and other locations

  • Long-term Safety and Tolerability of BHV-7000

    Sorry, accepting new patients by invitation only

    A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy

    Los Angeles 5368361, California 5332921 and other locations

  • Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the long-term safety in patients with TSC and refractory seizures who are currently receiving everolimus treatment in the Novartis-sponsored EXIST-3 study and who are determined to be benefiting from continued treatment as judged by the investigator at the completion of EXIST-3

    Los Angeles 5368361, California 5332921 and other locations

Our lead scientists for Seizures research studies include .

Last updated: